Trial Purpose

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT05947851

When speaking to your doctor, please have the trial identifier number available.

About The Trial

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in approximately 1,000 to 5,000 volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices.

Trial start Icon

Dates

  • Actual study start date August 8, 2023
  • Estimated primary completion date June 27, 2033
  • Estimated study completion date June 27, 2033

Eligibility

Conditions Icon

Conditions

CLL, Leukemia, Chronic Lymphocytic, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic, SLL, Small-Cell Lymphoma

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations